Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Completes Acquisition of ArcherDx

NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx.

The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing.  

"With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey," Invitae CEO Sean George said in a statement. "Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care."

Under the terms of the deal, Invitae acquired ArcherDx for $325 million in cash and 30 million shares of Invitae stock upfront. Additionally, Invitae may pay up to 27 million in shares of its common stock if certain milestones are met. The overall transaction is valued at around $1.4 billion.

In connection with the acquisition, Invitae borrowed $135.0 million under the credit agreement and guaranty with Perceptive Credit Opportunities Holdings III. The company has also issued to Perceptive warrants to purchase 1 million shares of Invitae's common stock. Separately, to help pay for the acquisition, Invitae sold 16.3 million shares of common stock for $275 million to certain accredited investors in a private placement.

Jason Myers, formerly ArcherDx CEO, was also appointed to Invitae's board of directors on Oct. 2 as part of the transaction. He will serve as president of oncology at Invitae.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.